Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1G | O43497 | 1/20 | 0.53 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.53 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.53 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.47 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.47 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 14/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6943657 | 0.84 | CACNA1G (0.57) | CACNA1GCACNA1BCACNA1CPARP1CACNA1H | |
| SCHEMBL11947879 | 0.83 | CACNA1G (0.44) | CACNA1GCACNA1BCACNA1CRIPK1PKN1 | |
| SCHEMBL16186544 | 0.83 | CACNA1G (0.56) | CACNA1GCACNA1BCACNA1CPARP1CACNA1H | |
| SCHEMBL15808861 | 0.83 | CACNA1B (0.57) | CACNA1GCACNA1BCACNA1CRIPK1CACNA1H | |
| SCHEMBL16186531 | 0.82 | CACNA1B (0.73) | CACNA1GCACNA1BCACNA1CPARP1CACNA1H | |
| SCHEMBL8324888 | 0.80 | CACNA1G (0.53) | CACNA1GCACNA1BCACNA1CPKN1PKN2 | |
| SCHEMBL15808970 | 0.80 | CACNA1B (0.53) | CACNA1GCACNA1BCACNA1CCACNA1H | |
| SCHEMBL15917113 | 0.79 | PTGES (0.62) | CACNA1GCACNA1BCACNA1C | |
| SCHEMBL6946091 | 0.78 | TDP1 (0.56) | CACNA1GCACNA1BCACNA1C | |
| SCHEMBL30689200 | 0.78 | TDP1 (0.56) | CACNA1GCACNA1BCACNA1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440542-B1 | Substituted benzimidazoles, benzonthiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2013-12-18 | — | — | EP | disclosed |
| US-8232288-B2 | Substituted benzimidazoles, benzothiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232288-B2 | Substituted benzimidazoles, benzothiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| US-8232288-B2 | Substituted benzimidazoles, benzothiazoles and benzoxazoles | GRUENENTHAL GMBH (DE) | 2012-07-31 | — | — | US | disclosed |
| EP-2440542-A1 | SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES | Grünenthal GmbH (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | GRUENENTHAL GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | GRUENENTHAL GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | GRUENENTHAL GMBH (DE) | 2011-01-13 | — | — | US | disclosed |
| WO-2010142402-A1 | SUBSTITUTED BENZIMIDAZOLES, BENZOTHIAZOLES AND BENZOXAZOLES | Grünenthal GmbH (DE) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009382-A1 | Substituted Benzimidazoles, Benzothiazoles and Benzoxazoles | BDKRB1, BDKRB2, BRD1 | CACNA1G 533/4885CACNA1B 1089/4885CACNA1C 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.